CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+30.56%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.93B
AUM Growth
+$1.93B
(+9.9%)
Cap. Flow
-$180M
Cap. Flow
% of AUM
-9.3%
Top 10 Holdings %
Top 10 Hldgs %
57.59%
Holding
37
New
5
Increased
6
Reduced
6
Closed
9
Top Buys
| 1 |
Gilead Sciences
GILD
|
$97.5M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$58M |
| 3 |
Ventas
VTR
|
$43.3M |
| 4 |
Pediatrix Medical
MD
|
$22M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$19.6M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$76.1M |
| 2 |
THOR
Synthorx, Inc. Common Stock
THOR
|
$60.3M |
| 3 |
AbbVie
ABBV
|
$37.9M |
| 4 |
DaVita
DVA
|
$37.5M |
| 5 |
Zymeworks
ZYME
|
$37.2M |
Sector Composition
| 1 | Healthcare | 95% |
| 2 | Real Estate | 2.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $191M | 9.73% | 1,000,000 | – | – |
|
2
Viatris
VTRS
$12.3B
| $176M | 8.95% | 8,750,000 +250,000 | +3% | +$5.03M |
|
3
Biogen
BIIB
$19.4B
| $104M | 5.29% | 350,000 | – | – |
|
|
4
Gilead Sciences
GILD
$140B
| $97.5M | 4.96% | +1,500,000 | New | +$97.5M |
|
5
Tenet Healthcare
THC
$16.3B
| $95.1M | 4.84% | 2,500,000 -650,000 | -21% | -$24.7M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $94.6M | 4.82% | 875,000 +25,000 | +3% | +$2.7M |
|
7
Ascendis Pharma
ASND
$11.8B
| $92.2M | 4.69% | 663,000 +13,000 | +2% | +$1.81M |
|
8
Brookdale Senior Living
BKD
$1.83B
| $90.9M | 4.62% | 12,500,000 | – | – |
|
9
Perrigo
PRGO
$3.27B
| $87.8M | 4.47% | 1,700,000 | – | – |
|
10
Alkermes
ALKS
$4.78B
| $84.2M | 4.28% | 4,125,000 +625,000 | +18% | +$12.8M |
|
11
Nektar Therapeutics
NKTR
$568M
| $80.9M | 4.12% | 3,750,000 +750,000 | +25% | +$16.2M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $77.4M | 3.94% | 600,000 -150,000 | -20% | -$19.4M |
|
|
13
DaVita
DVA
$9.85B
| $75M | 3.82% | 1,000,000 -500,000 | -33% | -$37.5M |
|
14
Universal Health Services
UHS
$11.6B
| $71.7M | 3.65% | 500,000 | – | – |
|
|
THOR
15
DELISTED
Synthorx, Inc. Common Stock
THOR
| $69.9M | 3.56% | 1,000,000 -862,116 | -46% | -$60.3M |
|
|
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $64.1M | 3.26% | 3,250,000 -250,000 | -7% | -$4.93M |
|
17
HCA Healthcare
HCA
$94.5B
| $59.1M | 3.01% | 400,000 -200,000 | -33% | -$29.6M |
|
|
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $58M | 2.95% | +730,000 | New | +$58M |
|
|
AMAG
19
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $53.4M | 2.72% | 4,390,000 | – | – |
|
20
Atara Biotherapeutics
ATRA
$84.6M
| $48.6M | 2.47% | 2,950,000 | – | – |
|
|
21
Ventas
VTR
$30.9B
| $43.3M | 2.2% | +750,000 | New | +$43.3M |
|
22
Myriad Genetics
MYGN
$593M
| $27.2M | 1.39% | 1,000,000 | – | – |
|
|
23
Pediatrix Medical
MD
$1.5B
| $22M | 1.12% | +790,000 | New | +$22M |
|
|
24
Teva Pharmaceuticals
TEVA
$21.1B
| $19.6M | 1% | +2,000,000 | New | +$19.6M |
|
|
CBIO
25
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $18.5M | 0.94% | 3,500,000 | – | – |
|